Huntsman Cancer Institute at the University of Utah is a nationally recognized research center and treatment hospital in Salt Lake City. We are the only National Cancer Institute-designated Comprehensive Cancer Center in the Mountain West and serve patients with all types of cancer from Utah, Idaho, Montana, Nevada, and Wyoming. In 2021, we opened the region’s first proton therapy center. We manage the Utah Population Database, the largest genetic database in the world. More genes for inherited cancers have been discovered at our institution than any place in the world, including genes for melanoma and breast, ovarian, colon, head, and neck cancers.
Immunotherapy and Targeted Therapies Continue to Improve Patient Outcomes in Lung Cancer
March 20th 2023Updated data from key trials in non–small cell lung cancer continue to demonstrate the superiority of immunotherapy and targeted therapy regimens for non–small cell lung cancer treatment, but the optimal use of these agents in the adjuvant vs neoadjuvant settings is still contested.
Teclistamab Approval Adds to Bucket of Relapsed/Refractory Multiple Myeloma Options
February 28th 2023Amandeep Godara, MBBS, expands on the advantages and limitations of teclistamab monotherapy in patients with late-relapsed myeloma, discusses the best use of bispecific antibodies and CAR T-cell therapy in this population, and highlights ongoing efforts to mitigate the impact of treatment-related toxicities and improve accessibility across the paradigm.
Talazoparib Plus Enzalutamide Improves rPFS in First-line mCRPC
Talazoparib plus enzalutamide generated a statistically significant and clinically meaningful improvement in radiographic progression-free survival vs placebo plus enzalutamide as first-line treatment for patients with metastatic castration-resistant prostate cancer, irrespective of homologous recombination repair status.
Patel Provides Insight Into Post-Transplant Complications in Myeloid Disorders
September 22nd 2022Dr Patel discusses post-transplant complications in myeloid disorders, the prevalence of these complications, and the most common ones that may arise, including primary disease relapse, graft-vs-host disease, infection, organ toxicity, persistent cytopenias, and immunosuppression.
Orteronel Plus ADT Misses OS End Point in Metastatic Hormone-Sensitive Prostate Cancer
The addition of orteronel to androgen deprivation therapy vs bicalutamide improved progression-free survival and prostate-specific antigen response in patients with metastatic hormone-sensitive prostate cancer, but missed the primary end point of overall survival in the phase 2 SWOG-1216 trial.
Biomarker Testing Will Fuel Next Wave of Treatment Innovations in Breast Cancer
Christos Vaklavas, MD, discusses the increasing emphasis on investigating tumor biology in breast cancer, plus the evolving treatment landscapes in HER2-positive breast cancer, hormone receptor–positive, HER2-negative breast cancer, and triple-negative breast cancer.
The Evolving Role of Prognostic Markers for CLL in the Era of Novel Agents
December 3rd 2021Deborah M. Stephens, DO, discusses her approach to treating a patients with chronic lymphocytic leukemia, how CAR T-cell therapy may fit into the treatment paradigm, and the numerous trials that have shown promise in this space.